CPC G06Q 30/0241 (2013.01) [A61K 31/437 (2013.01); A61K 31/4523 (2013.01); C12Q 1/6886 (2013.01); C12Q 2600/106 (2013.01)] | 15 Claims |
1. A method for extending duration of response to treatment in a patient having BRAFV600 mutation-positive unresectable or metastatic melanoma comprising administering to the patient (i) a first composition comprising [3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl][3-hydroxy-3-[(2S)-2-piperidinyl]-1-azetidinyl]methanone, or a pharmaceutically acceptable salt thereof, at a dose of 60 mg on days 1-21 of a 28 day cycle; and (ii) a second composition comprising propane-1-sulfonic acid {3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide, or a pharmaceutically acceptable salt thereof, at a dose of 960 mg twice daily on each day of the 28 day cycle.
|